Ipsen Deepens Ties with Exelixis to Enhance Treatment for Neuroendocrine Tumors
Tuesday, 2 July 2024, 07:34
Ipsen Expands Collaboration with Exelixis
Ipsen and Exelixis have strengthened their collaboration to enhance the treatment of advanced neuroendocrine tumors, focusing on the use of Cabometyx.
Strategic Move for Better Therapeutic Options
- Joint Commitment: Ipsen and Exelixis aim to improve treatment modalities for patients.
- Specialized Focus: The partnership targets advanced neuroendocrine conditions.
Their shared goal is to advance the field of neuroendocrine oncology.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.